Accelerating Antibiotic Drug Development: FDA Goes Beyond GAIN
This article was originally published in RPM Report
Executive Summary
FDA is sending a message to industry and Congress of its ongoing work to help companies with antibiotic drug development– beyond the requirements of the FDA Safety and Innovation Act.
You may also be interested in...
GAIN Begins (Part 1): FDA Completes Turnaround On Antibiotic R&D
In less than two years, FDA has moved from requiring unrealistic approval standards for antibiotics to exploring innovative ways to shorten the pathway for the most-needed drugs. And, surprise: Congress is on board too. After 15 years, there is finally real momentum on antibiotic drug policy. But is it all enough to get companies back in the game?
The Popularity of “Special Pop”: Antibiotics Incentives and PDUFA V
The Infectious Diseases Society of America’s “Special Population” approval mechanism has proponents within FDA and industry. That makes it look like a good balancing proposal to complement the market incentives for anti-infectives being pushed under the GAIN Act add-on to PDUFA V. There is one big hurdle, however: GAIN’s major legislative proponent, Rep. Phil Gingrey (R-GA) does not like the limitations on use post-approval.
FDA Catching Antibiotic Incentive Bug: Agency Primed To Consider Ways To Shorten Route for Resistant-Strain Drugs
FDA is working along a parallel path to other several other government agencies to find ways to stimulate drug development for anti-infectives active against resistant strains. Top policy leaders in the drug review divisions reflect the new interest by thinking aloud how historical controls or oncology-like accelerated approvals might speed the process.